CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)

Amylin and GLP-1 are two independent gut-brain satiety signals, and pairing them is one of the most mechanistically compelling weight-loss combinations currently under active development. Cagrilintide is a long-acting amylin analog designed for once-weekly subcutaneous dosing, engineered from native human amylin with a lipid side chain that extends its half-life to about 7 days. Native amylin and its short-acting analog pramlintide are released with insulin from pancreatic beta cells and slow gastric emptying, suppress postprandial glucagon, and enhance satiety via central amylin and calcitonin receptors. Cagrilintide provides that signal continuously, not just around meals. GLP-1 receptor agonists — semaglutide (pure GLP-1), tirzepatide (GLP-1 + GIP dual), and retatrutide (GLP-1 + GIP + glucagon triple) — drive weight loss primarily through central anorectic signaling, slowed gastric emptying, and insulin sensitization. The mechanisms overlap partially (both slow gastric emptying) but are largely additive: amylin agonism at calcitonin/amylin receptors is pharmacologically distinct from GLP-1 receptor agonism, and the two pathways converge on different central appetite circuits. The clinical hope is that stacking them extends the weight-loss ceiling beyond what either class achieves alone. The three variants differ only in the GLP-1 backbone. CagriSema is Novo Nordisk's formally developed co-administration of cagrilintide and semaglutide. CagriTriz — cagrilintide plus tirzepatide — is not a formal product (cagrilintide is Novo, tirzepatide is Lilly, and the two companies are direct competitors) and exists only as an off-label compounded or investigator-stacked combination. CagriReta — cagrilintide plus retatrutide — is similarly conceptual, with retatrutide not yet FDA-approved and no announced development program pairing it with an amylin analog. Most readers encountering these names are interested in CagriSema clinically and in the other two as theoretical maximalist stacks.

Cagrilintide binds both the amylin receptor (AMY, a heteromer of the calcitonin receptor with receptor activity-modifying proteins 1 and 3) and the calcitonin receptor itself. Activation slows gastric emptying, suppresses postprandial glucagon secretion, and reduces food intake through signaling to the area postrema and subsequent central anorectic circuits. Continuous weekly exposure provides tonic amylin-receptor engagement rather than the meal-linked pulses that native amylin supplies. The GLP-1 partner activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin secretion), on gastric smooth muscle (slowing emptying), and — critically for weight loss — on hypothalamic, brainstem, and vagal afferent neurons that integrate into central appetite control. Tirzepatide adds GIP receptor agonism, which further enhances insulin secretion and appears to contribute additional central anorectic signal; retatrutide adds glucagon receptor agonism on top, which raises resting energy expenditure and liver fat oxidation. The stacked effect is not simply additive arithmetic. Amylin and GLP-1 act on distinct central circuits and produce complementary profiles of satiety, delayed gastric emptying, and glucagon suppression. In the REDEFINE-1 trial, the full-dose cagrilintide 2.4 mg plus semaglutide 2.4 mg combination produced roughly 22.7% mean weight loss at 68 weeks versus about 15-16% with semaglutide alone — a meaningful incremental gain beyond either monotherapy. The pharmacologic rationale is that you are layering two independent gut-brain satiety axes rather than escalating a single axis.

CagriSema is the only variant with pivotal clinical evidence. Novo Nordisk's Phase 3 REDEFINE program includes REDEFINE 1 in obesity without diabetes and REDEFINE 2 in obesity with type 2 diabetes (both published in NEJM in 2025), plus REDEFINE 3, a cardiovascular outcomes trial that has not yet reported. REDEFINE 1 reported 20.4% mean body weight reduction at 68 weeks counting everyone randomized (22.7% if taken as intended) versus 3.0% with placebo, and REDEFINE 2 reported 13.7% versus 3.4%. In the open-label head-to-head REDEFINE 4 trial, however, CagriSema 2.4 mg/2.4 mg missed its non-inferiority goal against tirzepatide 15 mg (20.2% vs 23.6% weight loss at 84 weeks). Novo Nordisk submitted CagriSema 2.4 mg/2.4 mg to the FDA in December 2025, based on REDEFINE 1 and 2, and expects a decision in Q4 2026. No regulator had approved it as of October 2026. CagriTriz has no published clinical trial data as a formal product because cagrilintide (Novo) and tirzepatide (Lilly) are developed by competing companies. Any real-world use is through compounded pharmacies or off-label patient-initiated stacking, with no controlled efficacy or safety data specific to the combination. The mechanistic rationale is strong, but the evidence is absent. CagriReta is the most speculative of the three. Retatrutide itself is still investigational and has not been filed for approval: its pivotal Phase 3 obesity trials were published in September 2026 (TRIUMPH-1 in NEJM, 25.0% mean weight loss at 12 mg over 80 weeks; TRIUMPH-2 in the Lancet, in adults with type 2 diabetes), and Lilly plans to submit it to the FDA in Q1 2027. No announced development program combines it with cagrilintide. Any CagriReta combination would be theoretical until a formal program emerges or a compounding pharmacy produces one. The upside — amylin plus triple-agonist incretin — is pharmacologically dramatic on paper, but there is no efficacy or safety data to support it in humans.

In the REDEFINE trials, CagriSema's two components were escalated in parallel once weekly by subcutaneous injection: cagrilintide from 0.25 mg to 2.4 mg over roughly 16 weeks, and semaglutide from 0.25 mg to 2.4 mg on the standard Wegovy schedule. Full-dose maintenance is cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly. The version submitted to the FDA delivers the fixed 2.4 mg/2.4 mg combination from a single-use, dual-chamber prefilled pen. CagriTriz and CagriReta, where they exist, would pair cagrilintide (typically at the 2.4 mg dose used in CagriSema trials) with tirzepatide (standard weekly titration to 10-15 mg maintenance) or retatrutide (investigational; its Phase 3 TRIUMPH trials used 4, 9, and 12 mg weekly maintenance doses, reached by 4-week steps from a 2 mg start). These combinations are not developed products and have no established titration protocol; any real-world use is off-label and should be overseen by a clinician familiar with both components. All three combinations should be managed by a qualified clinician with baseline and periodic monitoring of weight, glycemia, and gastrointestinal tolerability. Dose escalation in parallel amplifies gastrointestinal side effects, particularly nausea and vomiting, and many protocols stagger or slow the titration on one component to improve tolerability.